Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: A randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa

Heart

Volumn 94, Issue 2, 2008, Pages 153-158

  Hughes, D A ^a,c   Elliott, P M ^b   Shah, J ^b   Zuckerman, J ^c   Coghlan, G ^c   Brookes, J ^d   Mehta, A B ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; ANTIHISTAMINIC AGENT; GLOBOTRIAOSYLCERAMIDE; HYDROCORTISONE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; PLACEBO; POLYSORBATE 20; SODIUM CHLORIDE; SODIUM DIHYDROGEN PHOSPHATE; ALPHA GALACTOSIDASE; CERAMIDE TRIHEXOSIDE;

ADULT; ARTICLE; CARDIOMYOPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; ENZYME REPLACEMENT; FABRY DISEASE; FOLLOW UP; HEART; HEART FUNCTION; HEART HYPERTROPHY; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HEART MUSCLE BIOPSY; HEART RIGHT BUNDLE BRANCH BLOCK; HUMAN; MALE; MORPHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; QRS COMPLEX; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URINE SEDIMENT; AGED; CHEMISTRY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ENZYMOLOGY; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HEART MUSCLE CONDUCTION SYSTEM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MAGNETIC RESONANCE ANGIOGRAPHY; METABOLISM; MIDDLE AGED;

ADULT; AGED; ALPHA-GALACTOSIDASE; CARDIOMYOPATHIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FABRY DISEASE; HEART CONDUCTION SYSTEM; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; MYOCARDIUM; TRIHEXOSYLCERAMIDES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 38749130497     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2006.104026     Document Type: Article

References (17)

1. Brady RO, Gal AE, Bradley RM, et al. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 1967;276:1163-7.
2. Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 2006;79:31-40.
3. Meikle PJ, Hopwood JJ, Clague AE, et al. Prevalence of lysosomal storage disorders. JAMA 1999;281:249-54.
4. Poorthuis BJ, Wevers RA, Kleijer WJ, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 1999;105:151-6.
5. Kuhn H, Kohler E, Hort W, et al. Concealed myocardial storage disease (Fabry's disease): pitfalls in the diagnosis of hypertrophic nonobstructive cardiomyopathy. Circulation 1982;66(Suppl 2):117.
6. Nakao S, Takenaka T, Maeda M, et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995;333:288-93.
7. Sachdev B, Takenaka T, Teraguchi H, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002;105:1407-11.
8. Linhart A, Lubanda JC, Palecek T, et al. Cardiac manifestations in Fabry disease. J Inherit Metab Dis 2001;24(Suppl 2):75-83; discussion 65.
9. Elleder M, Bradova V, Smid F, et al. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol 1990;417:449-55.
10. von Scheidt W, Eng CM, Fitzmaurice TF, et al. An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med 1991;324:395-9.
11. Schiffmann R, Kopp JB, Austin HA, et al. Enzyme replacement therapy in Fabry disease: a randomised controlled trial. JAMA 2001;285:2743-9.
12. Schiffmann R, Murray GJ, Treco D, et al. Infusion of α-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci U S A 2000;97:365-70.
13. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 2001;345:9-16.
14. Spinelli L, Pisani A, Sabbatini M, et al. Enzyme replacement therapy with agalsidase β improves cardiac involvement in Fabry's disease. Clin Genet 2004;66:158-65.
15. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57: 450-8.
16. Desnick RJ, Ioannou YA, Eng CM. α-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular basis of inherited disease. Seventh edition. Vol 2. New York: McGraw-Hill, 1995:2741-84.
17. Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345-52.